Compositions for detecting circulating integrin beta-3 biomarker and methods for detecting cancers and assessing tumor presence or progression, cancer drug resistance and tumor stemness
Cheresh, David A.,Seguin, Laetitia,Fujita, Yu,Weis, Sarah
申请号：
AU2016252621
公开号：
AU2016252621A1
申请日:
2016.04.20
申请国别(地区):
AU
年份:
2017
代理人:
摘要：
Provided are compositions and methods comprising use of beta-3 integrin for detecting circulating tumor cells (CTCs), tumor stem cells, extracellular vesicles (EVs), including exosomes and microvesicles, that are released by CTCs or cancer cells, and the tumor from which the CTCs or EVs derive, to make a patient prognosis, and to assess tumor progression, and drug resistance, e.g., for breast, colon, lung and pancreatic cancers. In alternative embodiments, a patient fluid sample, e.g., blood, is taken and used to detect cancer stem cells, EVs- and/or CTCs-comprising beta-3 integrin and/or alphavbeta3 integrin. Provided are compositions and methods using biomarker beta-3 integrin for anti-cancer drug design； and compositions and methods that include conjugation of an imaging or therapeutic agent to an antibody targeting integrin β3 for detection and/or targeted destruction of integrin beta-3 expressing cancer stem cells and/or CTCs.
